‘The undruggable became druggable’: a breakthrough cancer treatment
About this episode
The episode discusses a breakthrough cancer treatment that can double survival time for patients with a deadly cancer, featuring insights from a medical oncologist.
A daily pill can double survival time in patients with the world’s deadliest cancer, according to the results of a clinical trial that experts are saying is a gamechanger and one of the biggest breakthroughs in decades. To find out more about how daraxonrasib works and how life-changing it could be for patients, Madeleine Finlay speaks to Prof Naureen Starling, consultant medical oncologist at the Royal Marsden hospital. Help support our independent journalism at theguardian.com/sciencepod
People in this episode
Host: Madeleine Finlay
Guest: Prof Naureen Starling
Topics covered
- cancer treatment
- clinical trials
- medical breakthroughs
- oncology
- survival rates
Keywords
- cancer
- treatment
- daraxonrasib
- survival
- clinical trial
- oncologist
- breakthrough
Mentioned in this episode
Organizations: Royal Marsden hospital
Products: daraxonrasib
Places: world
More episodes of Science Weekly
- The dinosaurs who survived the asteroid
- Heatstroke, sports washing and VAR psychology: the science of the World Cup
- The incredible science of the sleeping brain
- Are robots nearing their ChatGPT moment?
- Do red-light masks really keep you looking young?
- Stateside with Kai and Carter: why the fight over abortion pills is only just beginning
Explore listener stats, chart rankings, contacts and more on the Science Weekly podcast page.